QIAGEN’s Cell and Gene Therapy Vector Integrity Roundtable
Our CSO David Dobnik discussed the available methods to assess vector genome integrity and the advantages dPCR-based solutions can bring. David shared his perspective on multiplex assay design to accomplish
Development of novel high-resolution multiplex digital PCR (HR-mdPCR) approach for detailed evaluation and quantification of vector genome or DNA impurities sequence integrity
The poster is prepared in collaboration with Stilla Technologies and was presented by our CSO David Dobnik at ESGCT Congress 2024 in Rome.
The Impact of Digital PCR on Quantification in Biopharma Research and Manufacturing
During an online conference held by Stilla, Assis. Prof. Dr. David Dobnik discussed the history of PCR technologies and the proprietary multiplex dPCR assay platform NIBAplex.
Development and qualification of 4-plex assay for AAV vector genome integrity evaluation by dPCR
The production of viral vectors for gene therapy is focused on pure, safe, and efficacious products. Absence of impurities and presence of full vector genomes play a crucial role. We
Multiplex dPCR and SV-AUC are Promising Assays to Robustly Monitor the Critical Quality Attribute of AAV Drug Product Integrity
Article published on ScienceDirect by David Dobnik, CSO and David B. Hayes
Measuring Viral Titer in AAV-Mediated Gene Therapy Using a PCR Technique for Absolute Quantitation
Article published on BioProcess International by David Dobnik, CSO.